Clinical TrialJun 22, 2026, 07:02 AM
Eledon Tegoprubart Phase 2 Data Shows Superior Kidney Function
AI Summary
Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplantation, presented at the American Transplant Congress. The data showed tegoprubart-treated patients maintained significantly higher mean eGFR at 18 months and experienced no biopsy-proven acute rejection events after the first six months post-transplant, unlike the tacrolimus arm. Patient-reported outcomes also favored tegoprubart, demonstrating improved symptom burden. Following a successful FDA End-of-Phase 2 meeting, Eledon plans to advance tegoprubart into Phase 3 clinical development in late 2026.
Key Highlights
- Tegoprubart-treated patients maintained 12 mL/min/1.73 m² higher mean eGFR at month 18 vs. tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05).
- No biopsy-proven acute rejection (BPAR) events observed in tegoprubart-treated patients after first six months post-transplant.
- Tacrolimus arm reported seven BPAR events (9.4%) after six months, including two after 12 months.
- Patient-reported outcomes at 52 weeks showed statistically significant improvements for tegoprubart on two validated measures.
- 96% of tegoprubart-treated patients entered the BESTOW long-term extension study.
- Eledon plans to initiate Phase 3 clinical development of tegoprubart in late 2026.
Price Impact
More from ELDN